22:35 , Jul 19, 2019 |  BioCentury  |  Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

A draft FDA guidance for heart failure endpoints could spark investment and accelerate development of cardiovascular therapies. But companies still don’t have a clear sense of when and whether they’ll need to gather mortality data...
21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
19:57 , Jun 18, 2019 |  BioCentury  |  Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells. Announced Tuesday, the cash infusion includes €28 million ($31.4...
21:03 , Jan 15, 2019 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A peptide that selectively activates the GABBR1a-splicing isoform of GABBR1 could be useful for probing the role of the isoform in Alzheimer’s disease (AD), epilepsy, schizophrenia and other neurological diseases. In vitro...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
15:21 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting VEGF-C could help treat AML. In bone marrow samples from pediatric patients, levels of VEGF-C were higher than in samples from...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016...
21:00 , Aug 22, 2018 |  BC Extra  |  Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016...
19:11 , Jul 27, 2018 |  BioCentury  |  Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...